Artelo Biosciences Inc.

AI Score

0

Unlock

1.16
0.03 (2.65%)
At close: Jan 15, 2025, 11:40 AM
undefined%
Bid 1.13
Market Cap 3.73M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.87
PE Ratio (ttm) -0.4
Forward PE n/a
Analyst Buy
Ask 1.16
Volume 12,959
Avg. Volume (20D) 34,370
Open 1.14
Previous Close 1.13
Day's Range 1.13 - 1.18
52-Week Range 0.91 - 1.75
Beta undefined

About ARTL

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2019
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ARTL

Analyst Forecast

According to 3 analyst ratings, the average rating for ARTL stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 419.48% from the latest price.

Buy 66.67%
Hold 0.00%
Sell 0.00%
Stock Forecasts
6 months ago · Source
+3.1%
Artelo Biosciences shares are trading higher after... Unlock content with Pro Subscription